TGFβR3基因3’UTR双荧光素酶报告载体的构建及其与miR-let-7a靶向关系的验证

摘要
图/表
参考文献
相关文章 (0)

全文: PDF (1637 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：构建III型转化生长因子β受体（TGFβR3）基因3’非编码区（3’UTR）双荧光素酶报告载体，并分析其与miR-let-7a的靶向关系。方法：根据microRNA靶基因预测软件targetscan获取miR-let-7a与TGFβR3基因3’UTR潜在的互补结合位点；PCR扩增出TGFβR3基因3’UTR序列并克隆至pGEM-T载体，定点突变潜在互补结合位点后双酶切pGEM-T载体获取目的片段并插入至双荧光素酶报告载体获得野生型和突变型重组双荧光素酶报告载体，测序鉴定；将2种载体分别与miR-let-7a mimics或miR-let-7a NC共同转染HEK293T细胞，收集细胞后通过双荧光素酶报告系统检测各组荧光素酶活性。结果：经测序鉴定成功构建野生型和突变型重组荧光素酶报告载体。双荧光素酶报告系统检测显示，共转染miR-let-7a mimics和野生型双荧光素酶报告载体的荧光素酶活性比miR-let-7a NC组明显降低（P＜0.05），而共转染突变型双荧光素酶报告载体后其荧光素酶活性差异无统计学意义（P＞0.05）。结论：成功构建TGFβR3基因3’UTR双荧光素酶报告载体，并证实TGFβR3基因是新发现的miR-let-7a直接靶向调控基因。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周欢栋
	顾睿
	吴大洲
	陈肖鸣

关键词 ： mioroRNAs；miR-let-7a；III型转化生长因子&beta, 受体；双荧光素酶报告载体

Abstract：Objective: To construct a luciferase reporter vector containing the 3’untranslated region (3’UTR) of TGFβR3 gene and evaluate the targeting correlation between TGFβR3 and miR-let-7a. Methods: The potential complementary binding sites of miR-let-7a and TGFβR3 were predicted by targetscan. The 3’UTR fragment of TGFβR3 amplified by PCR was firstly cloned into pGEM-T vector and the potential complementary binding sites was mutated. Then, the amplified fragment and the mutated fragment of TGFβR3 3’UTR were subcloned into pmirGLO dual-luciferase miRNA target expression vector within the PmeI/SalI restriction sites. The luciferase reporter vector and miR-let-7a mimics/miR-let-7a NC were co-transfected into HEK293T cells respectively. The relative luciferase activity was detected by luciferase reporter assay. Results: Results of double enzyme digestion and DNA sequencing confirmed that the luciferase reporter vector was successfully constructed. The relative luciferase activity of TGFβR3 3’UTR reporter vector and miR-let-7a mimics co-transfected group were decreased significantly comparing with miR-let-7a NC group (P<0.05), but the relative luciferase activity was no significance in TGFβR3 3’UTR mutated reporter vector. Conclusion: The luciferase reporter vector containing the 3’UTR-WT or 3’UTR-MUT of TGFβR3 is constructed successfully. And TGFβR3 is a direct novel target gene of miR-let-7a.

Key words： microRNAs miR-let-7a transforming growth factor beta receptor 3 luciferase reporter vector

收稿日期: 2016-11-21

基金资助:国家自然科学基金资助项目（81673643）；浙江省科技厅公益性技术应用研究项目（2012C23066）。

通讯作者: 陈肖鸣，主任医师，教授，硕士生导师，Email：cxm@wmu.edu.cn。

作者简介: 周欢栋（1990-），男，浙江诸暨人，硕士生。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2017/V47/I5/313

[1] KIM V N. Small RNAs: classification, biogenesis, and function[J]. Mol Cells, 2005, 19(1): 1-15.
[2] HOU X, WAN W, WANG J, et al. Let-7a inhibits migration of melanoma cells via down-regulation of HMGA2 expression[J]. Am J Transl Res, 2016, 8(9): 3656-3665.
[3] JIN B, WANG W, MENG X X, et al. Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway[J]. BMC Cancer, 2016, 16(1): 863.
[4] TANG R, YANG C, MA X, et al. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer[J]. Oncotarget, 2016, 7(5): 5972-5984.
[5] LANDI M T, ZHAO Y, ROTUNNO M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer[J]. Clin Cancer Res, 2010, 16(2): 430-441.
[6] CORSTEN M, HEGGERMONT W, PAPAGEORGIOU A P, et al. The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis[J]. Eur Heart J,2015, 36(42): 2909-2919.
[7] NAGPAL V, RAI R, PLACE A T, et al. MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis[J]. Circulation, 2016, 133(3): 291-301.
[8] PASQUINELLI A E, REINHART B J, SLACK F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA[J]. Nature, 2000, 408(6808): 86-89.
[9] TAKAMIZAWA J, KONISHI H, YANAGISAWA K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival [J].Cancer Res, 2004, 64(11): 3753-3756.
[10] YANG Q, JIE Z, CAO H, et al. Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C[J]. Carcinogenesis, 2011, 32(5): 713-722.
[11] ELDERBROOM J L, HUANG J J, GATZA C E, et al. Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion[J]. Mol Biol Cell, 2014, 25(16): 2320-2332.
[12] BüSSING I, SLACK F J, GROSSHANS H. let-7 microRNAs in development, stem cells and cancer[J]. Trends Mol Med, 2008, 14(9): 400-409.
[13] CHIU S C, CHUNG H Y, CHO D Y, et al. Therapeutic potential of microRNA let-7: tumor suppression or impeding normal stemness[J]. Cell Transplant, 2014, 23(4-5): 459-469.
[14] SU J L, CHEN P S, JOHANSSON G, et al. Function and regulation of let-7 family microRNAs[J]. Microrna, 2012, 1(1): 34-39.
[15] BARRETT L W, FLETCHER S, WILTON S D. Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements[J]. Cell Mol Life Sci, 2012,69(21): 3613-3634.
[16] JOHNSON S M, GROSSHANS H, SHINGARA J, et al. RAS is regulated by the let-7 microRNA family[J]. Cell, 2005, 120(5): 635-647.
[17] LEE Y S, DUTTA A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene[J]. Genes Dev, 2007, 21(9): 1025-1030.
[18] LI Y, ZHANG X, CHEN D, et al. Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2[J]. Tumour Biol, 2016, 37(6): 8107-8119.
[19] TIAN B, HUO N, LI M, et al. let-7a and its target, insulin like growth factor 1 receptor, are differentially expressed in recurrent prostate cancer[J]. Int J Mol Med, 2015, 36(5):1409-1416.
[20] MURRAY M J, SAINI H K, SIEGLER C A, et al. LIN28 Expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels[J]. Cancer Res, 2013, 73 (15): 4872-4884.
[21] WANG X F, LIN H Y, NG-EATON E, et al. Expression cloning and characterization of the TGF-beta type III receptor[J]. Cell, 1991, 67(4): 797-805.
[22] LóPEZ-CASILLAS F, PAYNE H M, ANDRES J L, et al. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites[J]. J Cell Biol, 1994, 124(4): 557-568.
[23] KIRKBRIDE K C, TOWNSEND T A, BRUINSMA M W, et al. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor[J]. J Biol Chem, 2008,283(12): 7628-7637.
[24] KIRKBRIDE K C, RAY B N, BLOBE G C. Cell-surface co-receptors: emerging roles in signaling and human disease [J]. Trends Biochem Sci, 2005, 30(11): 611-621.
[25] XU D, LI D, LU Z, et al. Type III TGF-β receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-κB signaling[J]. Oncol Rep, 2016, 35(1): 267-274.
[26] BANDYOPADHYAY A, LóPEZ-CASILLAS F, MALIK S N, et al. Antitumor activity of a recombinant soluble betagly can in human breast cancer xenograft[J]. Cancer Res, 2002,62(16): 4690-4695.
[27] BANDYOPADHYAY A, ZHU Y, MALIK S N, et al. Extra cellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells[J]. Oncogene, 2002, 21(22): 3541-3551.